Tian'an Technology Group Ltd
Tian'an Technology Group Ltd is a holding company whose operating activities are carried out through subsidiaries in Hong Kong and mainland China. Its business centers on healthcare-related products and services, including graphene-based far-infrared heat therapy products, healthcare product sales, and healthcare service development in China.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueGraphene-enabled products that use far-infrared heat therapy properties.
Sale of healthcare-related products through operating subsidiaries.
Healthcare service offerings provided through the Henan subsidiary.
AI software development and related digital healthcare capabilities.
Planned digital platform for medication delivery to customers.
Customers
The company serves customers in the healthcare and wellness market, with initial marketing efforts focused on Eastern China. Its products and services are aimed at buyers seeking graphene-based therapy products, healthcare goods, and access to healthcare services. The planned medicine distribution platform also points to end users needing more convenient medication delivery.
Buy graphene-based far-infrared therapy products for personal wellness use.
Purchase healthcare-related products sold through Shanghai Qige and Tian'an HK.
Use healthcare services offered through Henan Qige in China.
Use the planned online medicine distribution channel for medication delivery.
Strategy
The company is building a healthcare-focused business around graphene therapy products, healthcare services, and related digital distribution capabilities. Its stated priorities include expanding from Eastern China toward a broader national marketing footprint and adding adjacent healthcare service and software offerings to deepen its market reach.
It broadens the company's addressable market beyond a single product concept.
Services can create recurring customer relationships and diversify the business mix.
An online medicine platform can support broader customer access and convenience.
A wider sales network is needed to scale beyond the Eastern China launch area.
Geography
The company is organized across the British Virgin Islands, Hong Kong, and mainland China, but its operating business is primarily conducted in the PRC. Management has said initial marketing is concentrated in Eastern China, with plans to build a nationwide network over time. This makes mainland China the core commercial market and also the main source of regulatory and operating exposure.
Risks
The business is exposed to China operating, regulatory, and currency-related risks because substantially all operations are conducted in the PRC. It also faces execution risk as it moves from product sales into healthcare services, AI software, and online distribution, which require different capabilities, compliance standards, and customer adoption.
- PRC regulatory and policy riskImpact: HighLikelihood: High
Operations are primarily conducted in China, so changes in laws or policy can directly affect sales and services.
Exposure: Healthcare products and healthcare services in the PRC
- Execution risk in new healthcare initiativesImpact: HighLikelihood: Medium
The company is extending from product sales into healthcare services, AI software, and online pharmacy distribution.
Exposure: Henan Qige services and planned distribution platform
- Foreign exchange and remittance restrictionsImpact: MediumLikelihood: Medium
The company reports in USD but operates principally in RMB and HKD, creating translation and transfer risk.
Exposure: RMB/HKD operating cash flows and intercompany funding
- Customer demand and market acceptance riskImpact: MediumLikelihood: Medium
Graphene therapy products and related health offerings depend on customer adoption and perceived efficacy.
Exposure: Graphene far-infrared heat therapy products
Accounting
Judgemental itemsOperating currencies are principally RMB and HKD while reporting is in USD.
Impact: Can move reported assets, liabilities, and results without cash change.
Due to related parties is a significant balance in the financial statements.
Impact: Affects liquidity analysis and must be understood in consolidation context.
The company has product sales, healthcare services, and planned online distribution.
Impact: Timing and classification of revenue may differ by activity.
The balance sheet includes both cash and restricted cash.
Impact: Affects liquidity interpretation and available working capital.
Similar listed companies
Publicly listed companies with a comparable business focus.
PMA Graphene Technology Group Inc.
PMA · Construction - Special Trade Contractors
BGM Group Ltd.
BGM · Pharmaceutical Preparations
BGM Group Ltd is a Cayman Islands holding company with operating businesses primarily conducted through subsidiaries and variable interest entities in mainland China.
iTonic Holdings Ltd
ITOC · Electromedical & Electrotherapeutic Apparatus
iTonic Holdings Ltd is a U.S.-listed healthcare solutions company organized around Beijing Feitian Zhaoye Technology Co., Ltd., its wholly owned operating subsidiary in Beijing, China.
Longduoduo Co Ltd
LDDD · Services-Health Services
Longduoduo Co Ltd is a U.S.-listed company with operating subsidiaries in Inner Mongolia and Beijing that generates revenue from two main activities: direct…
Scientific Energy, Inc
SCGY · Patent Owners & Lessors
Zhongchao Inc.
ZCMD · Services-Educational Services
Last updated: 28/09/2026